J&J(US:JNJ) Prnewswire·2026-02-21 13:00Core Insights - Johnson & Johnson announced long-term data from the QUASAR study showing that TREMFYA® (guselkumab) maintains clinical and endoscopic remission in ulcerative colitis patients over three years, with over 80% of patients in clinical remission and more than 50% in endoscopic remission at Week 140 [1][2]. Group 1: Clinical Efficacy - At Week 140, 80.8% of patients treated with TREMFYA® were in clinical remission, while 53.6% achieved endoscopic remission [1]. - 78.6% of patients experienced histo-endoscopic mucosal improvement (HEMI), indicating significant intestinal healing [1]. - Among those in clinical remission at Week 44, 87.5% maintained remission through Week 140, demonstrating sustained efficacy [1]. Group 2: Study Retention and Safety - Approximately 89% of eligible study participants completed treatment through Week 140, indicating high retention rates [1]. - No new safety concerns were reported during the study, reinforcing the long-term safety profile of TREMFYA® [1][2]. Group 3: Mechanism and Approval - TREMFYA® is the first and only approved dual-acting monoclonal antibody that blocks IL-23 and binds to CD64, targeting immune-mediated diseases [1][2]. - The drug has received FDA and European Commission approval for treating both moderately to severely active Crohn's disease and ulcerative colitis [1][2]. Group 4: Additional Research and Commitment - Johnson & Johnson presented 30 abstracts at the European Crohn's and Colitis Organisation (ECCO) 2026 conference, highlighting ongoing research and commitment to inflammatory bowel disease treatments [1]. - Two other abstracts from Johnson & Johnson were recognized as Top 10 oral abstracts, showcasing the company's dedication to advancing treatment options [1].